Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DME Suppliers Spotlighted In OIG Joint Venture Kickbacks Advisory

This article was originally published in The Gray Sheet

Executive Summary

The Bush Administration is accelerating efforts to block kickbacks arising from contractual joint ventures in the health care system, highlighting durable medical device manufacturers and dialysis supply centers as common violators

You may also be interested in...



OIG personnel shake-up

HHS Inspector General Janet Rehnquist decides to resign effective June 1. The move follows the receipt by Finance Committee Ranking Democrat Max Baucus (D-Mont.) and Senate Finance Chairman Charles Grassley (R-Iowa) of a draft GAO investigation on recent personnel changes at OIG and how they may compromise OIG's ability to police fraud. Rehnquist's departure is appropriate "under the circumstances," according to Baucus who was preparing to ask for Rehnquist's resignation before she announced her intention to step down on March 6, according to a Senate aide. A draft of the report will be available by the end of March...

FTC/DoJ Health Care Hearings To Evaluate Consumer Protection Mandate

The Federal Trade Commission will review the effect of its consumer protection mandate on the disclosure of costs, risks and benefits by device manufacturers at hearings scheduled to begin in February

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel